Tegopep

Product Name:Tegopep

Form:TFA Salt

Purity:98%

Storage:2-8 degree Celsius

Cas No:1036207-61-0

Molar Mass:500.6

Chemical Formula:C22H40N6O7

Synonyms:Tetrapeptide-30

IUPAC Name:6-amino-2-[[2-[[6-amino-2-(pyrrolidine-2-carbonylamino)hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoic acid

SMILES:C1CC(NC1)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)O

InChIKey:LYHZXMVNRVAAJA-UHFFFAOYSA-N

InChI:InChI=1S/C22H40N6O7/c23-11-3-1-6-15(26-19(31)14-8-5-13-25-14)20(32)27-16(9-10-18(29)30)21(33)28-17(22(34)35)7-2-4-12-24/h14-17,25H,1-13,23-24H2,(H,26,31)(H,27,32)(H,28,33)(H,29,30)(H,34,35)

Sequence:PKEK

Application:

TEGO® Pep 4-Even is a bioactive tetrapeptide (Tetrapeptide-30) designed to brighten skin tone, reduce hyperpigmentation, and improve overall skin evenness. It works by inhibiting tyrosinase gene expression, effectively reducing melanin synthesis and addressing uneven pigmentation. This peptide also exhibits significant anti-inflammatory properties, helping to reduce redness and acne lesions. Clinical studies have demonstrated that TEGO® Pep 4-Even visibly diminishes hyperchromatic spots and alleviates melasma, making it suitable for all skin types, including ethnic skin. Commonly incorporated into skin-lightening preparations, anti-aging products, and formulations targeting pigmentation disorders, it offers a safe and effective solution for achieving a more radiant and uniform complexion.

Current Research:

TEGO® Pep 4-Even (Tetrapeptide-30) is a synthetic tetrapeptide developed to target hyperpigmentation, uneven skin tone, and inflammatory skin conditions. It is particularly recognized for its ability to regulate melanin synthesis by inhibiting tyrosinase gene expression, offering a gentle yet effective alternative to traditional skin-lightening agents.

Mechanism of Action: Inhibition of Melanin Synthesis
Hyperpigmentation occurs due to an overproduction of melanin triggered by UV exposure, inflammation, or hormonal imbalances. TEGO® Pep 4-Even counteracts these processes by:

Suppressing Tyrosinase Gene Expression – reducing the enzyme’s activity responsible for melanin production.
Inhibiting Excessive Melanin Formation – leading to a more even skin tone over time.
Reducing Inflammation and Post-Inflammatory Hyperpigmentation (PIH) – calming irritation that can trigger excessive pigmentation.
This dual-action mechanism not only prevents the formation of new dark spots but also reduces existing hyperpigmentation, making the skin appear brighter, clearer, and more uniform.

Clinical Studies and Efficacy
Multiple clinical studies have demonstrated that TEGO® Pep 4-Even is highly effective in reducing visible pigmentation:

Improves Skin Tone Evenness – Studies have shown that consistent application leads to a significant reduction in facial age spots and hyperchromatic lesions within six weeks.
Brightens the Skin – When incorporated into brightening serums, this peptide lightens overall skin tone without irritation, making it suitable for sensitive and ethnic skin.
Reduces Acne-Related Hyperpigmentation – Clinical trials indicate a visible decrease in post-acne marks and redness, leading to a more even complexion.
Comparison with Other Brightening Agents
Unlike hydroquinone or kojic acid, which may cause skin irritation and sensitivity, TEGO® Pep 4-Even provides a gentler approach to skin brightening by addressing both the pigmentation process and inflammation. It is also less aggressive than retinoids, making it ideal for long-term skin tone correction.

Future Research and Applications
Ongoing research is exploring the synergy of Tetrapeptide-30 with vitamin C, niacinamide, and other brightening agents to enhance its depigmenting effects. Additionally, it is being tested for use in post-inflammatory pigmentation treatments and anti-aging formulations that address skin discoloration alongside wrinkle reduction.

With its proven ability to regulate melanin production, improve skin brightness, and reduce hyperpigmentation safely, TEGO® Pep 4-Even is a breakthrough ingredient in modern skincare formulations, particularly in brightening serums, anti-aging creams, and pigmentation-correcting treatments.

Reference:

Neubert, R. H., Sommer, E., Schölzel, M., Tuchscherer, B., Mrestani, Y., & Wohlrab, J. (2018). Dermal peptide delivery using enhancer moleculs and colloidal carrier systems. Part II: Tetrapeptide PKEK. European Journal of Pharmaceutics and Biopharmaceutics, 124, 28-33.